A Randomized, Open-label Study Comparing the Systemic Exposure to Triamcinolone Acetonide Following a Single Intra-articular Dose of Extended-release FX006 or Immediate-release TAcs (Triamcinolone Acetonide Suspension) in Patients With Osteoarthritis of the Shoulder (Glenohumeral Joint) or Hip
Latest Information Update: 08 Jan 2024
At a glance
- Drugs Triamcinolone (Primary) ; Triamcinolone
- Indications Osteoarthritis
- Focus Adverse reactions; Pharmacokinetics
- Acronyms SHIP
- Sponsors Flexion Therapeutics
- 09 Aug 2021 Results published in the Flexion Therapeutics Media Release.
- 04 Aug 2021 Results (n=25) evaluating pharmacokinetics, safety and tolerability of single triamcinolone acetonide extended-release 32 mg or triamcinolone acetonide crystalline suspension 40 mg in patients with shoulder osteoarthritis , published in the Drugs in R and D
- 02 Jan 2019 Results presented in a Flexion Therapeutics media release.